PHILADELPHIA / Jul 11, 2024 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA).
In February 2024, the World Health Organization (WHO) recommended the removal of B/Yamagata strains from seasonal influenza vaccines.1 The WHO recommends that egg-based trivalent vaccines for the 2024-2025 northern hemisphere influenza season contain the following:1
In partnership with regulatory bodies, GSK worked quickly to ensure production, approval and availability of trivalent influenza vaccines with the recommended composition for the 2024-25 flu season.
GSK expects to distribute over 36 million doses of its trivalent influenza vaccines in the US this season. Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months of age and older.
According to the US Centers for Disease Control and Prevention (CDC), annual influenza vaccination is the best way to help protect against the flu. Ideally, vaccination should occur by the end of October, but people should continue to get vaccinated as long as the flu poses a threat.2 CDC recommends an annual flu vaccination for anyone aged six months or older who does not have contraindications.2
CDC estimates that from October 1, 2023, through June 15, 2024, there have been 35 – 65 million flu illnesses, 390,000 – 830,000 flu hospitalizations and 25,000 – 72,000 flu deaths.3
About Influenza
The flu (influenza) is a contagious respiratory illness caused by influenza viruses that infect the nose, throat and sometimes the lungs. It can cause mild to severe illness and at times can lead to death.4
Anyone can get the flu, however, it can be serious for young children, adults 65 years and older, pregnant women and people with pre-existing chronic health conditions, such as asthma, diabetes and heart disease.5
For more information about the flu, visit https://www.cdc.gov/flu/about/keyfacts.htm.
Indication for FLUARIX and FLULAVAL
FLUARIX and FLULAVAL are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccines. FLUARIX and FLULAVAL are approved for use in persons aged 6 months and older.
Important Safety Information for FLUARIX and FLULAVAL
Please see full Prescribing Information for FLUARIX and for FLULAVAL.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, and Q1 Results for 2023 and any impacts of the COVID-19 pandemic.
References | |
1. | World Health Organization. Recommendations announced for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season. Available at: https://www.who.int/news/item/23-02-2024-recommendations-announced-for-influenza-vaccine-composition-for-the-2024-2025-northern-hemisphere-influenza-season. Accessed June 17, 2024. |
2. | Centers for Disease Control and Prevention. Influenza (Flu) Preventative Actions. Available at: https://www.cdc.gov/flu/prevent/prevention.htm. Accessed June 17, 2024. |
3. | Centers for Disease Control and Prevention. 2023-2024 Preliminary In-Season Burden Estimates. Available at: https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm. Accessed June 17, 2024. |
4. | Centers for Disease Control and Prevention. Key Facts About Influenza (Flu). Available at: https://www.cdc.gov/flu/about/keyfacts.htm. Accessed June 17, 2024. |
5. | Centers for Disease Control and Prevention. About Flu. Available at: https://www.cdc.gov/flu/about/index.html. Accessed June 14, 2024. |
Last Trade: | US$43.67 |
Daily Change: | 0.54 1.25 |
Daily Volume: | 3,722,987 |
Market Cap: | US$89.090B |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB